

Abgenix Incorporated

[View the current Abgenix Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/56-Abgenix+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/56-Abgenix+Incorporated.html>)

Contact Details:

7601 Kaiser Drive

Fremont

CA

94555

United States of America

Tel: 510 608 6500

Fax: 510 608 6511

Email: busdev@abgenix.com

Abgenix is a biopharmaceutical company focused on the development and commercialization of human therapeutic antibodies. The company's technology platform, which includes XenoMouse® and XenoMax™ technologies, enables the rapid generation and selection of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology by building a diversified product portfolio through the development of its own internal proprietary products and through the establishment of licensing arrangements with multiple pharmaceutical, biotechnology and genomics companies. Abgenix's proprietary products are currently in clinical trials for the treatment of cancer and inflammatory diseases.

Recent Publications by Abgenix Incorporated:



- [Elimination mechanisms of therapeutic monoclonal antibodies.](#)
*Targeted therapies using monoclonal antibodies have achieved important...*17th March, 2006
Abgenix, Pharmacokinetics & Toxicology, 6701 Kaiser Drive, Fremont, CA- Drug Discov Today. 2006 Jan;11(1-2):81-8. ([DOI Direct Link](#))
- [The removal of pyroglutamic acid from monoclonal antibodies without denaturation of the protein chains.](#)
*Typically, the removal of pyroglutamate from the protein chains of...*12th October, 2005
Abgenix Corporation,- Anal Biochem. 2005 Jul 1;342(1):120-5. ([DOI Direct Link](#))
- [Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8.](#)
*The high specificity and affinity of monoclonal antibodies make them...*27th September, 2005
Abgenix Biopharma Inc., Burnaby, BC, Canada.- Biochem Biophys Res Commun. 2005 Sep 9;334(4):1004-13. ([DOI Direct Link](#))

- [eBLOCKs: enumerating conserved protein blocks to achieve maximal sensitivity and specificity.](#)
*Classifying proteins into families and superfamilies allows identification...*16th April, 2005
Abgenix, Inc., 6701 Kaiser Drive, MS 11, Fremont, CA 94555, USA.- Nucleic Acids Res. 2005 Jan 1;33(Database issue):D178-82. ([DOI Direct Link](#))
- [Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods.](#)
*Two biophysical methods, Biacore and KinExA, were used to kinetically and...*16th December, 2004
Abgenix, Inc., 6701 Kaiser Drive, Fremont, CA 94555, USA.- Anal Biochem. 2004 May 1;328(1):35-43. ([DOI Direct Link](#))
- [A novel method of Multiplexed Competitive Antibody Binning for the characterization of monoclonal antibodies.](#)
*We have developed a novel method of high-throughput Multiplexed...*11th August, 2004
Abgenix, Inc., 6701 Kaiser Drive, Fremont, CA 94555, USA.- J Immunol Methods. 2004 May;288(1-2):91-8. ([DOI Direct Link](#))
- [pDNA bioparticles: comparative heterogeneity, surface, binding, and activity analyses.](#)
*New applications for nucleic acid-bound micro/nanoparticles are emerging...*21st July, 2004
Abgenix, Fremont, CA 94555, USA.- Biochem Biophys Res Commun. 2004 Jun 25;319(2):426-32. ([DOI Direct Link](#))
- [High cell density induces spontaneous bifurcations of dissolved oxygen controllers during CHO cell fermentations.](#)
*High cell density cultures of CHO cells growing in a bioreactor under...*20th May, 2004
Abgenix Inc, 6701 Kaiser Drive, Fremont, California 94555, USA.- Biotechnol Bioeng. 2003 Oct 20;84(2):224-32. ([DOI Direct Link](#))
- [Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.](#)
*PURPOSE: The aim of the study was to investigate the effect of histidine...*21st April, 2004
Department of Process Sciences, Abgenix, Inc., Fremont, CA 94555, USA.- Pharm Res. 2003 Dec;20(12):1952-60.
- [Production of human antibodies from transgenic mice.](#)
*Two biophysical methods, Biacore and KinExA, were used to kinetically and...*30th March, 2004
Abgenix Inc, Fremont, CA, USA.- Methods Mol Biol. 2004;248:191-200.
- [Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.](#)
*The epidermal growth factor receptor (EGFR) is a transmembrane...*25th March, 2004
Abgenix, Inc., Fremont, CA, USA.- Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90. ([DOI Direct Link](#))
- [Application of factorial design to accelerate identification of CHO growth factor requirements.](#)
*To accelerate recombinant CHO media and process development, we describe a...*8th October, 2003
Department of Process Science, Abgenix Inc., 6701 Kaiser Drive, Fremont,- Biotechnol Prog. 2003 Jan-Feb;19(1):52-7. ([DOI Direct Link](#))
- [Heat inactivation of mammalian cell cultures for biowaste kill system design.](#)
*A biowaste kill system was implemented to treat biological waste generated...*8th October, 2003
Abgenix, Inc., Department of Process Sciences, 6701 Kaiser Dr., MS26,- Biotechnol Prog. 2003 Jan-Feb;19(1):14-20. ([DOI Direct Link](#))
- [Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics.](#)
*Technical advances made in the 1980s and early 1990s resulted in...*22nd May, 2003
Abgenix, Inc., 6701 Kaiser Drive, Fremont, CA 94555, USA.- Curr Opin Biotechnol. 2002 Dec;13(6):593-7.

Press Releases on Abgenix Incorporated:

H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics	20th November, 2009	Quest Diagnostics Incorporated	-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during
New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)	20th November, 2009	Quest Diagnostics Incorporated	MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services,
Spherix Announces the Closing of \$6.3 Million Registered Direct Offering	19th November, 2009	Spherix Incorporated	BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting
Spherix Announces Results of Annual Shareholders Meeting	19th November, 2009	Spherix Incorporated	-- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods International In addition, Grant Thornton LLP was ratified as the Company's independent accountants
Give Your Pooch the Gift of Wisdom This Holiday	19th November, 2009	Mars Veterinary	ROCKVILLE, Md., Nov. 19 /PRNewswire/ -- There is no greater love than the adoration you receive from man's best friend. This holiday season, return the love by gifting your four legged friend

BioNews Results for Abgenix Incorporated



- [Renowned Bioprocess Expert to Join Intrexon](#)
Pharma Live: Oct 30 2009 6:14PM Matching: abgenix
- [Renowned Bioprocess Expert to Join Intrexon](#)
Genetic Engineering News: Oct 28 2009 5:58PM Matching: abgenix
- [Renowned Bioprocess Expert to Join Intrexon](#)

- Freshnews.com: Oct 28 2009 4:39PM Matching: abgenix*
- [Renowned Bioprocess Expert to Join Intrexon](#)

NewsBlaze: Oct 28 2009 4:14PM Matching: abgenix

 - [Renowned Bioprocess Expert to Join Intrexon](#)

TradingMarkets: Oct 28 2009 3:51PM Matching: abgenix

 - [Renowned Bioprocess Expert to Join Intrexon](#)

Forbes.com: Oct 28 2009 3:39PM Matching: abgenix

 - [Renowned Bioprocess Expert to Join Intrexon](#)

RBC Dain Rauscher: Oct 28 2009 3:37PM Matching: abgenix

 - [Renowned Bioprocess Expert to Join Intrexon](#)

Yahoo! Canada: Oct 28 2009 3:36PM Matching: abgenix

 - [Renowned Bioprocess Expert to Join Intrexon](#)

PR inside: Oct 28 2009 3:36PM Matching: abgenix

 - [Renowned Bioprocess Expert to Join Intrexon](#)

Street Insider: Oct 28 2009 3:33PM Matching: abgenix

 - [Renowned Bioprocess Expert to Join Intrexon](#)

Business Wire UK: Oct 28 2009 3:28PM Matching: abgenix

 - [Renowned Bioprocess Expert to Join Intrexon](#)

Business Wire: Oct 28 2009 3:19PM Matching: abgenix

 - [ImmunoGen Announces Amgen has Licensed Rights to Use the Company's TAP Technology for a Solid Tumor Target](#)

Stockwatch: Sep 16 2009 8:28PM Matching: abgenix

 - [ImmunoGen Announces Amgen has Licensed Rights to Use the Company's TAP Technology for a Solid Tumor Target](#)

Business Wire via Yahoo!: Sep 16 2009 8:12PM Matching: abgenix

Abgenix Incorporated Clinical Trials:



- [ABX-EGF \(a Monoclonal Antibody\) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body](#)

Abgenix Incorporated Patents:



- 7563442- [Antibodies to CD40 and methods of treating cancer and enhancing immune responses](#)
- 6673986- [Generation of xenogeneic antibodies](#)
- 6657103- [Human antibodies derived from immunized xenomice](#)
- 6458592- [Production of antibodies using cre-mediated site-specific recombination](#)

- 6420140- [Production of multimeric protein by cell fusion method](#)
- 6395515- [Directed switch-mediated DNA recombination](#)
- 6235883- [Human monoclonal antibodies to epidermal growth factor receptor](#)
- 6207418- [Production of a multimeric protein by cell fusion method](#)
- 6162963- [Generation of Xenogenetic antibodies](#)
- 6150584- [Human antibodies derived from immunized xenomice](#)
- 6130364- [Production of antibodies using Cre-mediated site-specific recombination](#)
- 6114598- [Generation of xenogeneic antibodies](#)
- 6091001- [Production of antibodies using Cre-mediated site-specific recombination](#)
- 6075181- [Human antibodies derived from immunized xenomice](#)
- 5998209- [Generation of large genomic DNA deletions](#)
- 5985615- [Directed switch-mediated DNA recombination](#)
- 5939598- [Method of making transgenic mice lacking endogenous heavy chains](#)
- 6677138- [Production of a multimeric protein by cell fusion method](#)
- 6682736- [Human monoclonal antibodies to CTLA-4](#)
- 6833268- [Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions](#)
- 7422742- [Methods for using human monoclonal antibodies to interleukin-5](#)
- 7338660- [Methods of treating cancer and enhancing immune responses with antibodies that bind CD40](#)
- 7326414- [Antibodies to M-CSF](#)
- 7288251- [Antibodies to CD40](#)
- 7202343- [Antibodies directed to monocyte chemo-attractant protein-1 \(MCP-1\) and uses thereof](#)
- 7145056- [Production of antibodies using cre-mediated site-specific recombination](#)
- 7141653- [Human monoclonal antibodies to interleukin-5](#)
- 7109003- [Methods for expressing and recovering human monoclonal antibodies to CTLA-4](#)
- 7090844- [Use of antibodies against the MUC18 antigen](#)
- 7078492- [Human antipneumococcal antibodies from non-human animals](#)
- 7067131- [Methods for using anti-MUC18 antibodies](#)
- 7064244- [Transgenic mammals having human Ig loci including plural V.sub.H and V.sub.K regions and antibodies produced therefrom](#)
- 7049426- [Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions](#)
- 7037498- [Antibodies to insulin-like growth factor I receptor](#)
- 6924360- [Antibodies against the MUC18 antigen](#)
- 6884622- [Method for preparing a mammalian cell deficient in HPRT](#)
- 5916771- [Production of a multimeric protein by cell fusion method](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic

- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

